Classification of breast cancer molecular subtypes based on contrast-enhanced ultrasound and superb microvascular imaging using machine learning approach

基于对比增强超声和超微血管成像的乳腺癌分子亚型机器学习分类

阅读:1

Abstract

BACKGROUND: Varying patterns of angiogenesis are observed across molecular subtypes of breast cancer (BC). This study aimed to develop and validate machine learning (ML) models for identifying molecular subtypes of BC using contrast-enhanced ultrasound (CEUS) and superb microvascular imaging (SMI). METHODS: In this prospective study, 191 BC patients with 193 lesions were enrolled. Clinical data, CEUS parameters, and SMI features were collected; recursive feature elimination was applied for feature selection. Random forest (RF), support vector machine (SVM), and logistic regression (LR) were trained to distinguish molecular subtypes, and their diagnostic performances were compared. Model interpretability was achieved using SHapley Additive exPlanations (SHAP). RESULTS: BC lesions were randomly assigned to training (n=135) and test (n=58) cohorts in a 7:3 ratio. Fivefold cross-validation with five repetitions was utilized for hyperparameter tuning. SVM effectively distinguished luminal subtypes, achieving area under the curves (AUCs) of 0.955 [95% confidence interval (CI): 0.914-0.996] for training and 0.874 (95% CI: 0.769-0.979) for testing. RF outperformed other models for human epidermal growth factor receptor 2 (HER2)-overexpressed subtype, with AUC of 0.944 (95% CI: 0.902-0.986) and 0.872 (95% CI: 0.768-0.975) in training and test cohorts, respectively. LR excelled in differentiating triple-negative breast cancer (TNBC), yielding AUC of 0.846 (95% CI: 0.758-0.933) and 0.824 (95% CI: 0.704-0.943). CONCLUSIONS: Incorporating CEUS and SMI features into an ML approach may enhance the diagnostic capacity for distinguishing molecular subtypes of BC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。